Compare Citius Pharmaceuticals Inc (CTXR) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Gitlab Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Gitlab Inc trades at $33.32 (market cap $5.57B). The key difference: Gitlab Inc is far larger — about 380.5× Citius Pharmaceuticals Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | GTLB | |
|---|---|---|
Market Cap | $14.64M | $5.57B |
Sector | Health | Technology |
52-Week High | $1.82 | $51.04 |
52-Week Low | $0.53 | $19.42 |
Enterprise Value | $10.86M | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
GitLab (GTLB) trades at $33.47, up 3.24% today, with a bullish technical signal from moving averages and a consensus analyst price target of $31.93. The company reported strong revenue growth to $759.25 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven platform expansions, including a collaboration with Google Cloud.
The outlook is mixed; robust revenue growth and strategic positioning in AI and DevSecOps offer upside, but profitability challenges and high valuation multiples pose risks. Analyst sentiment is cautious with a majority hold rating, reflecting concerns over near-term execution versus long-term potential in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
